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Abstract
Background: It is generally accepted that all arthroplasty patients should receive venous thromboembolism (VTE)
and bleeding risk assessments, and that postoperative thromboprophylaxis be routinely prescribed where appropriate.
Guideline recommendations regarding what to prescribe, however, have been inconsistent over the years, particularly
regarding the appropriateness of aspirin. Our aim was to explore thromboprophylaxis patterns in use following hip and
knee arthroplasty in Australia, and to examine associated variables.
Methods: Orthopaedic surgeons were invited via mail to participate in two national surveys, conducted in 2012 (N =
478) and 2017 (N = 820), respectively.
Results: The final response rates were 50.0 and 65.8% for 2012 and 2017, respectively. The thromboprophylaxis
prescribing routines reported by respondents were divided into four categories: anticoagulant-only (the
same anticoagulant-only routine for everyone), aspirin-only (aspirin for everyone), staged-supply (an
anticoagulant during the initial postoperative period, followed by aspirin, for everyone) and risk-stratification
routines (differing regimens depending on patients’ perceived risk of VTE). The most common approaches
reported were anticoagulant-only routines; however, their popularity almost halved within the five-year
period (from ~ 74% to ~ 41%). Conversely, staged-supply and risk-stratification protocol usage increased by
more than two and nine times, respectively. In 2017, over one-half of surgeons reported prescribing aspirin in
their practice. Reported concern for postoperative VTE and infections (OR 0.555 95% CI 0.396–0.779, p = 0.001
and OR 1.455 95% CI 1.010–2.097, p = 0.044 respectively), as well as Arthroplasty Society membership (OR 2.814
95% CI 1.367–5.790, p = 0.005) were predictors for use of aspirin (Cox and Snell R square = 0.072). The factor
most commonly reported to shape surgeons’ protocols was research literature. Factors limiting prescribing of
pharmacological prophylaxis included a perception that it increases bleeding and wound infection risk, is
inconvenient, and lacks evidence applicable to real-world practice.
Conclusions: VTE prevention post-arthroplasty is an evolving and multi-faceted entity, influenced by a range of
factors and seemingly in need of robust evidence from large clinical trials to guide practice. The data
highlighted potential short-falls in practice related to aspirin over-use, which could be further explored and
addressed in future studies in order to optimise patient outcomes and reduce the significant morbidity and
healthcare costs associated with VTE following these increasingly common surgical procedures.
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Background
Hip and knee arthroplasties are increasing worldwide. In
Australia [1, 2] and the United Kingdom (UK) [3], an-
nual procedure numbers almost doubled and more than
tripled between 2003 and 2016, respectively. Although
comparable data is limited, similar trends have also been
described in the United States of America (USA) [4, 5].
These trends have potentially significant repercussions
given that both procedures are considered risk factors
for a leading cause of death and disability worldwide,
namely venous thromboembolism (VTE) [6].
To reduce the risk of VTE post-arthroplasty, it is gen-
erally agreed that following individual VTE and bleeding
risk assessments, postoperative thromboprophylaxis
should be routinely prescribed for all patients. Guideline
recommendations regarding what to prescribe, however,
have been at variance with one another over the years,
particularly regarding the appropriateness of aspirin as a
thromboprophylactic agent [7–15]. The American Asso-
ciation for Orthopaedic Surgeons (AAOS) chose not to
provide any recommendations for or against specific
prophylactics in its guideline, however its Australian
counterpart, the Arthroplasty Society of Australia (work-
ing under the auspices of the Australian Orthopaedic
Association) has listed aspirin as an appropriate agent in
at least the last three editions of its guideline, for
patients at ‘low’ or ‘routine’ risk of VTE following
arthroplasty [7–9, 15]. In 2012 the American College of
Chest Physicians (ACCP) recommended aspirin as an
appropriate prophylactic agent post-arthroplasty (with
preference given to low molecular weight heparin over
aspirin); this was in stark contrast to their previous 2008
guideline which specifically recommended against using
aspirin as a sole agent [10, 11]. Until recently, the UK’s
National Institute for Health and Care Excellence
(NICE), like the Australian National Health and Medical
Research Council (NHMRC), recommended against the
use of aspirin post-arthroplasty [12, 13]. In the recent
NICE guideline, however, there are recommendations
for its use both following initial anticoagulant use (for
hip arthroplasty patients) and alone (for knee arthro-
plasty patients), with no specific advice regarding when
to use an aspirin-inclusive regimen over an
anticoagulant-only one or vice versa [14]. These vari-
ances in recommendations regarding aspirin may inad-
vertently lead to either its over or under utilisation,
thereby needlessly exposing patients to VTE and/or the
risks associated with prophylactic and therapeutic
anticoagulation.
We previously reported on a survey of Australian hip
and knee surgeons examining thromboprophylaxis pref-
erences, conducted in 2010 [16]. Given the varying and
changing local and international recommendations
regarding thromboprophylaxis post-arthroplasty, we
have conducted two follow-up surveys, 5 years apart (in
2012 and 2017) to explore changes in the thrombopro-
phylaxis patterns in use in Australia.
Methods
The study was designed as a cross-sectional exploratory
study, employing quantitative surveys conducted 5 years
apart to meet its aims. The two surveys were conducted
separately, each receiving ethics approval from the
Tasmanian Social Science Human Research Ethics
Committee.
Study 1
An address list of Australian hip and knee surgeons was
compiled by searching practice listings, hospital
websites, and the internet. Invitations to participate were
mailed to 478 surgeons in May 2012, with reminders
sent two and 4 weeks later. Surgeons could complete an
enclosed hard-copy or access the survey online; most
participants completed hard-copies (95.9%).
Study 2
The address list was updated using a similar search
strategy, but also included searches of the online Royal
Australasian College of Surgeons (RACS) Find a Surgeon
directory (a directory of surgeons who voluntarily opt to
have their contact details listed on the site). Invitations
and surveys were mailed to 820 surgeons in June 2017,
with reminders sent 3 and 7 weeks later. Given the prior
preference for completing hard-copies, an online option
was not provided.
The surveys were modified versions of a previously
conducted survey, with both collecting data on respon-
dents’ demographics, familiarity with guidelines, and
practices and opinions regarding thromboprophylaxis
and its efficacy [16]. The survey tool used in 2017 col-
lected additional data regarding factors that influence
surgeons’ practice, and surgeons’ level of concern
regarding post-arthroplasty complications. They are
available for viewing on the BMC Musculoskeletal
Disorders website (Additional file 1: Appendix A and
Additional file 2: Appendix B).
Statistical analysis
Data was analysed using SPSS (Statistical Package for
the Social Sciences) 25.0 (IBM® Armonk, New York,
USA). Continuous variables were summarised as
means with standard deviations (SD). The differences
between groups were tested using the t-test for inde-
pendence and one-way analysis of variance with
Tukey’s honest significant difference for continuous
data, and chi-square test for categorical variables.
Pearson’s rank coefficients were calculated for meas-
uring correlations. Logistic regression analyses were
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conducted to assess which variables (such as: years
practising, annual surgery load, sector of practice,
ASA membership and reported level of concern for
various postoperative complications) were most
closely associated with surgeons’ preference to use or
not use aspirin and other measures to minimise VTE
in their practice, over and above mechanical and
pharmacological prophylaxis. Multiple regression ana-
lyses were conducted to explore relationships between
the level of concern reported by surgeons for different
postoperative complications and other continuous var-
iables (such as: years practising, annual surgery load
and reported level of concern for other postoperative
complications). Only p values ≤0.05 were considered
statistically significant.
Results
The final response rates were 50.0 and 65.8%, respect-
ively (Table 1). Compared to Study 1, respondents in
Study 2 conducted less arthroplasties, were less likely to
be members of the Arthroplasty Society of Australia
(ASA), and were less likely to conduct their clinical prac-
tice in the private sector.
Thromboprophylaxis routines and associated variables
Pharmacological preferences
The thromboprophylaxis prescribing routines reported
by respondents were divided into four categories: antic-
oagulant-only (providing the same anticoagulant-only
routine for everyone), aspirin-only (providing aspirin for
everyone), staged-supply (providing an anticoagulant
during the initial postoperative period, followed by as-
pirin, for everyone) and risk-stratification routines (pro-
viding differing regimens depending on patients’
categorisation as being either at ‘routine-risk’ or ‘high--
risk’ of VTE). Most surgeons who performed both pro-
cedures preferred to use the same thromboprophylaxis
prescribing routine type for both patient groups [191,
99.5%, N = 192 (Study 1); 364, 95.8%, N = 380 (Study 2)].
Many surgeons in both studies reported prescribing
thromboprophylaxis beyond the initial hospital stay i.e.
extended thromboprophylaxis therapy [168, 80.0%, N =
210 (Study 1); 384, 94.3%, N = 409 (Study 2)]. The mean
reported duration of therapy was slightly higher for rou-
tine hip patients compared to knee patients [28.9, SD
14.1 days vs. 22.4, SD 15.1, p < 0.001 (Study 1); 36.6, SD
16.3 vs. 30.9, SD 16.9 days, p < 0.001 (Study 2)].
Excluding the Northern Territory, which only had two
respondents, anticoagulant-only routines were the only
protocol used throughout the country in 2012; in 2017,
all except aspirin-only protocols were represented na-
tionwide. While anticoagulant-only routines were the
most popular approach in both studies (Table 2), their
reported preference almost halved between surveys.
Similarly, the number of surgeons who reportedly pre-
ferred to use aspirin-only routines in their practice, irre-
spective of their patients’ perceived VTE risk, also
reduced between the two studies. However, the increase
in the number of surgeons preferring risk-stratification
protocols suggests there is an actual increase in the
number of surgeons prescribing aspirin for patients. The
most popular of the risk-stratification routines used as-
pirin for ‘routine-risk’ patients and an anticoagulant for
‘high-risk’ patients. The top three patient factors associ-
ated with being classified as ‘high-risk’ by these surgeons
were a personal history of VTE, active cancer and pro-
longed preoperative immobility (Fig. 1). In contrast,
most preferred aspirin in patients with preoperative
infection (75, 72.8%, N = 103) or a high falls risk (90,
85.7%, N = 105).
Table 1 Surgeon responses and respondent demographics for
Study 1 and Study 2
Study 1
2012
Study 2
2017
Surgeons invited 478 820
Returned responses 257 596
Responses/Surgeons excluded
due to …
36 165
...surgeon death / retirement /
moving overseas
25 13
...invite being returned unopened – 83
...surgeon not being a hip or knee
surgeon
11 69
Surveys included (%) N 221 (50.0) 442 431 (65.8) 655
Male gender (%) 217 (98.6) 220 416 (97.4) 427
Years practising [mean (SD)] n 17.8 (9.0) 213 17.6 (9.7) 424
Sector of practice (%) **
Private practice predominantly 155 (70.5) 247 (59.5)
Public practice predominantly 10 (4.5) 50 (12.0)
Both sectors equally 55 (25.0) 118 (28.4)
Relevant scope of practice (%)
Hip only 3 (1.4) 3 (0.7)
Knee only 22 (10.0) 46 (10.7)
Both 194 (87.8) 381 (88.4)
Not specified 2 (0.9) 1 (0.2)
Annual arthroplasty load
[mean (SD)] n *
175.2 (102.9)
215
157.5 (108.6)
423
Hip arthroplasties per year 76.3 (52.0)
193
68.5 (57.8)
376
Knee arthroplasties per year 108.3 (67.6)
212
97.3 (71.2)
420
ASA membership (%) * 48 / 209
(23.0)
62 / 425
(14.6)
* p < 0.05; ** p < 0.005; ASA = Arthroplasty Society of Australia; ASA members
specialise in arthroplasty surgery and at least 80% of their surgeries must be
joint replacements. SD = standard deviation
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A quarter of respondents in Study 1 (54, 24.9%, N =
217) and over half in Study 2 (246, 57.1%, N = 431)
reported using aspirin in their protocol, either in a
staged-supply, risk-stratification or aspirin-only protocol;
these surgeons are hereafter referred to as aspirin-pre-
scribers. Reported level of concern for VTE and surgical
site infections (SSI), as well as ASA membership were
statistically significant predictors for use of aspirin (Cox
and Snell R square = 0.072) in Study 2. Visual analogue
scales (VAS) were used in the survey to explore respon-
dents’ level of concern for postoperative complications,
including VTE and SSI, with a score of 0 indicating they
were not concerned at all, and a maximum score of 3
indicating they were very concerned. For every unit
increase in the VAS score related to VTE concern (e.g.
from 1 to 2), the odds of the surgeon being an
aspirin-prescriber reduced by a factor of 0.555 (95% CI
0.396–0.779, p = 0.001). Conversely, for every unit in-
crease in their score related to SSI concern, the odds of
the surgeon being an aspirin-prescriber increased by a
factor of 1.455 (95% CI 1.010–2.097, p = 0.044). Being an
ASA member increased the odds of a surgeon being an
aspirin-prescriber by a factor of 2.814 (95% CI 1.367–
5.790, p = 0.005). There were no significant variables
in Study 1. In 2012 only two surgeons specified a
total daily aspirin dose (100 mg and 300 mg). In 2017
the most commonly specified total daily dose was
100 mg (120, 62.5%), followed by 150 mg (39, 20.3%),
300 mg (25, 13.0%), 200 mg (6, 3.1%), 75 mg (1, 0.5%)
and 500 mg (1, 0.5%, N = 192).
Table 2 Pharmacological routine type preferences for hip and knee arthroplasty in Study 1 and Study 2
Study 1
(N = 221)
Study 2
(N = 431)
Hip
n = 197 (%)
Knee
n = 216 (%)
Hip
n = 384 (%)
Knees
n = 427 (%)
Anticoagulant-only 144 (73.1) 161 (74.5) 155 (40.4) 176 (41.2)
Staged-supply 16 (8.1) 19 (8.8) 76 (19.8) 86 (20.1)
Risk-stratification 9 (4.6) 10 (4.6) 143 (37.2) 156 (36.5)
Routine patients: Aspirin only
High Risk patients: Anticoagulant only
2 (1.0) 2 (0.9) 103 (26.8) 116 (27.2)
Routine patients: Anticoagulant, then aspirin
High Risk patients: Extended anticoagulant therapy
1 (0.5) 1 (0.5) 24 (6.3) 28 (6.6)
Routine patients: Anticoagulant as inpatient only
High Risk patients: Extended anticoagulant therapy
– – 6 (1.6) 6 (1.4)
Routine patients: Aspirin only
High Risk patients: Anticoagulant, then aspirin
– – 1 (0.3) 1 (0.2)
Protocol unclear, however employs anticoagulants
and aspirin in a risk-stratification protocol.
6 (3.0) 7 (3.2) 9 (2.3) 5 (1.2)
Aspirin-only 25 (12.7) 23 (10.6) 7 (1.8) 6 (1.4)
Miscellaneousa – – 2 (0.5) 2 (0.5)
Thromboprophylaxis protocol not reported 3 (1.3) 3 (1.4) 1 (0.3) 1 (0.2)
aNB: Miscellaneous incorporates surgeons whose reported practice did not fit into any of the other categories e.g. prescribing a non-steroidal anti-inflammatory
agent other than aspirin
Fig. 1 Factors classifying patients as ‘high-risk’ in risk-stratification protocols involving aspirin and anticoagulants (Study 2 only)
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Most respondents reported using anticoagulants [193,
88.9%, N = 217 (Study 1); 424, 98.6%, N = 430 (Study 2)];
of these, most preferred injectable agents alone, and gen-
erally enoxaparin (Fig. 2). Regarding the dosing of anti-
coagulants, only 14 surgeons in Study 1 reported an
actual dose, all of whom reported prescribing the recom-
mended dose for thromboprophylaxis for each agent in
Australia (i.e. apixaban 2.5 mg twice daily, dalteparin
2500 or 5000 units daily, enoxaparin 20 mg or 40 mg
daily, rivaroxaban 10mg daily etc.). In Study 2, most sur-
geons who disclosed their preferred anticoagulant
agent(s) also reported a dose (336, 96.8%, N = 347), al-
most unanimously using either the recommended dose
for thromboprophylaxis for the agent (315, 93.8%) or
adjusting the dose to patients’ total body weight, lean
body mass or body mass index (17, 5.1%, N = 336).
Where reported, warfarin INR target ranges were either
1.5 to 2.0, 1.5 to 2.5, or 2.0 to 2.5 (4, 5.7%, N = 7).
Mechanical preferences (study 2 only)
Most surgeons reported using mechanical prophylaxis
(403, 95.3%, N = 423). Of those with a stated preference
(N = 376), compressive devices were most common (338,
89.9%), either alone (174, 51.5%) or with thrombo-
embolic stockings (164, 48.5%, N = 338). Of these, calf
compressive devices were the most popular (214, 63.3%,
N = 338), used either alone (189, 88.3%) or in combin-
ation with venous foot pumps (25, 11.7%, N = 214).
Aspirin-prescribers reported employing mechanical
prophylaxis marginally more often than their
counterparts (97.5% vs 92.2%, p = 0.018, N = 423), and
tended to be more likely to prefer a compression device
(92.5% vs. 85.9%, p = 0.053, N = 376).
Other measures to minimise VTE risk (study 2)
Three hundred and forty surgeons reported taking mea-
sures over and above postoperative mechanical and
pharmacological prophylaxis to minimise VTE risk
post-arthroplasty (78.9%, N = 431), with early mobilisa-
tion being the most commonly reported measure (311,
91.5%, N = 340, Table 3). The logistic regression model
explained only 5.7% of the variance (Cox and Snell R
square). Aspirin-prescribers were more likely to report
taking measures over and above mechanical and
pharmacological prophylaxis (OR 1.834 95%CI 1.093–
3.044, p = 0.006), as were surgeons who practiced pre-
dominantly in the private sector (compared to surgeons
who practiced in the public sector either predominantly
or equally, OR 2.558 95%CI 1.529–4.274, p < 0.001). The
measures reported by respondents are outlined in Table 3
in three categories: those that occur pre-surgery, during
surgery, and post-surgery. In addition to those listed, 10
surgeons (2.9%) reported avoiding operating on smokers
(n = 9) and/or the morbidly obese (n = 5), three surgeons
(0.9%) reported using an enhanced-recovery-after-surgery
protocol, which typically involves components of care
across all three care stages, [17] and five (1.5%) reported
providing patients with VTE risk minimisation education,
although it was unclear when this occurs (N = 340).
Fig. 2 Anticoagulant and agent preferences (Study 1 (N = 217 and 193); Study 2 (N = 430, and 347). Legend: Study 1; Study 2
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Protocol-shaping factors (study 2 only)
Three hundred and nine surgeons (71.7%, N = 431) listed
at least one factor that had shaped their thrombopro-
phylaxis protocol, the most common of which was
research literature (125, 40.5%, N = 309, Table 4).
Two-fifths (28, 43.1%, N = 65) of those who cited bleed-
ing, wound and/or infections, specifically referred to an-
ticoagulants (e.g. ‘excessive bleeding with enoxaparin
and rivaroxaban’).
Although relatively few respondents listed guidelines
as having influenced their protocol (n = 48), three times
as many stated elsewhere that they used one (or more)
in practice (n = 144, 55.4%, N = 260). The most com-
monly cited guideline was the ASA guideline (82,
56.9%), followed by the AAOS (34, 23.6%), NHMRC (17,
11.8%), ACCP (13, 9.0%), Australian and New Zealand
Working Party (ANZWP, 5, 3.5%) and NICE (3, 2.1%)
guidelines. A further 56 (21.5%) surgeons reported using
an amalgamation of unspecified guidelines, 22 reported
using a local hospital guideline (8.5%), and 38 specifically
reported not using them (14.6%).
Surgeons who preferred risk-stratification protocols
were more likely to report using the ASA, AAOS and/or
ACCP guidelines in practice (43.6%) compared to sur-
geons who preferred staged-supply (31.3%), aspirin-only
(16.7%) or anticoagulant-only (11.9%) protocols (p <
0.001). Surgeons who preferred using anticoagulant-only
protocols were the most likely to report using the
NHMRC, ANZWP and/or NICE guidelines in practice
(9.7% vs. 0–2.4% for other protocols, p = 0.004). Sur-
geons who preferred using aspirin-only protocols were
the most likely to categorically state that they did not
use a guideline (33.3% vs. 3.4–11.4% for other protocols,
p = 0.007).
Guideline familiarity
Self-reported guideline familiarity was explored with
respondents, irrespective of whether they reported using
them or not. Over half reported being very familiar with
orthopaedic-specific (AAOS and ASA) guidelines; similar
high-level familiarity with multi-disciplinary guidelines
was generally only reported by ≤40% of respondents
(Fig. 3). Nevertheless, reported guideline familiarity
broadly improved between studies. In Study 2, surgeons
who reported being very familiar with the AAOS, ACCP,
ANZWP, ASA or NHMRC guidelines were more likely to
specifically report using that guideline compared with sur-
geons who marked that they had either not come across it
or had only heard of it in passing (12.8% vs. 1.5% p <
0.001; 6.1% vs. 1.3% p = 0.009; 4.8% vs. 0.0% p = 0.001;
27.1% vs. 3.0% p < 0.001; 10.6% vs. 0.0% p < 0.001,
respectively).
Factors limiting pharmacological prophylaxis use
In both studies, surgeons were asked to indicate if any
factors limited their pharmacological prophylaxis use. In
Table 3 Other measures reportedly used by surgeons to
minimise VTE risk (N = 340)
Measure Frequency (%)
Pre-surgery
Prescribes exercise, weight loss, hydro and/or
physiotherapy, and requires patients be smoke-free
for 6 weeks prior to surgery
4 (1.2)
Avoids patients on HRT or ceases it pre-surgery 4 (1.2)
Admits patients on day of surgery 3 (0.9)
During surgery
Regional anaesthesia 41 (12.1)
Avoids/minimises tourniquet use 24 (7.1)
Intra-articular anaesthesia 11 (3.2)
Intraoperative mechanical prophylaxis 9 (2.6)
Ensures minimal operation times 3 (0.9)
Intraoperative heparin 2 (0.6)
Avoids bilateral operations 1 (0.3)
Inferior vena cava filter (with warfarin) in high risk
patients
1 (0.3)
Post-surgery
Early mobilisation 311 (91.5)
Hydration 23 (6.8)
Ankle and bed exercises 20 (5.9)
Limb elevation 9 (2.6)
Early hospital discharge 3 (0.9)
Ensures ‘good’ postoperative analgesia 2 (0.6)
Table 4 Factors reported to shape surgeons’
thromboprophylaxis protocols (N = 309)
Protocol-shaping factor Frequency (%)
Research literature 125 (40.5)
Patient complications 78 (25.2)
Bleeding, wound and/or infections 65 (21.0)
VTE 7 (2.3)
Fatal VTE 6 (1.9)
Experience 84 (27.2)
Guidelines 48 (15.5)
Colleagues 39 (12.6)
Local Protocols 27 (8.7)
Meetings/Conferences/Lectures 26 (8.4)
Patient convenience and compliance concerns 18 (5.8)
Medico-legal concerns 16 (5.2)
Training 10 (3.2)
Increasing obesity 1 (0.3)
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Study 2, this question addressed aspirin and anticoagu-
lants separately. The top two factors were a perceived in-
creased risk of bleeding and wound infections (Fig. 4).
As rated on the VAS in Study 2 (0 = not concerned at all
to 3 = very concerned), 89.8% of surgeons reported being
concerned/very concerned about SSI, 70.5% about major
bleeding, and 49.5% about minor bleeding; 80.2% said
they were concerned/very concerned about patients de-
veloping postoperative VTE. These variables were statis-
tically related in the multiple regression analysis. In
particular, the biggest predictor for level of concern for
VTE was reported level of concern for SSI (adj R square
= 0.215, semipartial correlation coefficient = 0.216, p <
0.001), the biggest predictor for level of concern for SSI
was reported level of concern for major postoperative
bleeding (adj R square = 0.293, semipartial correlation
coefficient = 0.322, p < 0.001) and the biggest predictor
for level of concern for major postoperative bleeding
was reported concern for minor bleeding (adj R square
= 0.409, semipartial correlation coefficient = 0.317, p <
0.001), followed by reported level of concern for SSI
(semipartial correlation coefficient = 0.295, p < 0.001).
The number of years a surgeon had been practising was
also a statistically significant predictor of level of con-
cern for SSI (semipartial correlation coefficient = − 0.118,
p = 0.004) and reported level of concern for major post-
operative bleeding (semipartial correlation coefficient =
0.170, p < 0.001). There were no correlations with
arthroplasty load.
The third factor most commonly identified as limiting
respondents’ pharmacological use post-arthroplasty was
a perception that it is inconvenient, especially regarding
anticoagulants in Study 2 (Fig. 4). Following closely be-
hind was a perception that study evidence applicable to
real-world practice is lacking. Correspondingly, less than
half of respondents were confident that pharmacological
prophylaxis was effective at reducing the incidence of
fatal PE or overall mortality (Fig. 5). Aspirin-prescribers
were more likely than their counterparts to believe as-
pirin was effective in preventing fatal PE (13.5% vs. 4.8%,
p = 0.004) and overall mortality (30.7% vs 11.5%, p <
0.001), and were less likely to believe anticoagulants
were effective [(16.9% vs. 26.6%, p = 0.021) and (12.1% vs
20.1%, p = 0.037)] (Study 2 data only). They were also
more likely to report lacking study evidence as being a
limiting factor to anticoagulant prescribing (43.7% vs.
23.1%, p < 0.001) compared to their counterparts, who
were more likely to report it as being a limiting factor to
aspirin use (6.1% vs 13.5%, p = 0.050).
Discussion
Our surveys indicate that thromboprophylaxis practices
following hip and knee arthroplasty are highly variable,
and increasingly so, in Australia. Although the protocol
Fig. 3 Guideline familiarity reported by respondents in Studies 1 and 2. Legend: Not come across before; Heard of in passing; Very
familiar with
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type most commonly reported to be used in practice
(anticoagulant-only) aligned with national recommenda-
tions at the time, our findings suggest that its popularity is
declining. In its place, risk-stratification and staged-supply
protocols are gaining momentum, neither of which were
officially recommended at the time. Their rise in popular-
ity and spread may be directly reflective of their increasing
literature representation over the 5 years [18]. Interest-
ingly, both protocols are recommended in some measure
in the recent NICE guideline [14]. We anticipate that this
Fig. 4 Factors limiting respondents’ pharmacological thromboprophylaxis use (Study 1N = 221, Study 2N = 301); *added in 2017. Legend: Inpatient
and Discharge pharmacological prophylaxis use (Study 1); Inpatient and Discharge aspirin use (Study 2); Inpatient and Discharge
anticoagulant use (Study 2). Total proportion of surgeons who answered the question in and
Fig. 5 Surgeons’ opinions regarding pharmacological prophylaxis efficacy (Study 1, N = 208; Study 2, N = 403 to 413). Legend: Pharmacological
prophylaxis (Study 1); Aspirin and Anticoagulant prophylaxis (Study 2)
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– combined with the recent release of the EPCAT II study
[19] results – will encourage their further widespread use.
Of note, at the time of writing, the evidence for
aspirin-only protocols in hip arthroplasty patients specif-
ically was limited, and they are not recommended in the
recent NICE guideline [14, 18]. Nevertheless, almost one
in three hip surgeons in our Study 2 cohort reported
using aspirin-only routines in hip arthroplasty patients,
either by employing a blanket approach or as part of a
risk-stratification protocol. Furthermore, approximately
one third of both hip and knee surgeons in Study 2 who
said they preferred risk-stratification protocols did not
consider active cancer or a personal history of VTE as
factors that would classify their patient as being at high
risk of VTE, and thus unsuitable for aspirin-only treat-
ment. Together, these practices may be unnecessarily
exposing patients to the risk of VTE and its associated
treatment with therapeutic anticoagulation. Further,
well-designed research investigating the efficacy and
safety of aspirin-only routines in hip arthroplasty pa-
tients is needed to explore this more thoroughly.
That approximately 50% of surgeons in 2017 were
using protocols which were not recommended at the
time, but now are in some measure (i.e. risk-
stratification and staged-supply protocols) [14],
illustrates practice preceding guidelines. This is likely
due to the laborious process of guideline production and
its associated negative impact on the ability of profes-
sional bodies (esp. multi-disciplinary ones) to make rapid
recommendations based on new data. In contrast, sur-
geons review and discuss research and conference
papers as they are released, allowing greater speed and
agility in implementing their findings. Correspondingly,
the factor most commonly cited as having shaped
respondents’ thromboprophylaxis practice was research
literature. Although compared to Study 1, many more
surgeons in Study 2 marked a lack of study evidence
applicable to real-world practice as limiting their throm-
boprophylaxis prescribing, most of these responses
related to anticoagulant use, with relatively few surgeons
indicating that a lack of study evidence limited their
aspirin use.
The second most commonly reported protocol-shaping
factor was surgeons’ experience, particularly regarding
postoperative complications. That so many more cited
bleeding and wound issues, compared to VTE outcomes,
is likely due to ‘bleeding being a much more readily
apparent complication for the surgeon whose experience of
VTE will be limited due to the overall low incidence of
clinical VTE, and the majority of VTE events occurring
after hospital discharge’ [20]. This limited exposure, par-
ticularly to fatal VTE, may explain why an increasing
majority of surgeons in our study did not confidently be-
lieve that pharmacological prophylaxis prevents fatal PE.
Furthermore, given its very low incidence, there is a short-
age of clinical trials that are sufficiently powered to show
statistically significant reductions in fatal PE. It is not sur-
prising that surgeons are far from overwhelmingly con-
vinced on the matter. Fatal PE is, however, only one cause
of mortality following arthroplasty, and research suggests
that it is not the leading cause; myocardial infarction is
[21]. Given aspirin’s well-established role in the secondary
prevention of cardiovascular disease, it is perhaps under-
standable why surgeons were more confident in the ability
of aspirin to reduce overall mortality (compared to
anticoagulants).
The third most commonly listed protocol-shaping fac-
tor was guidelines, and there were trends between sur-
geons’ preferred protocol and the guideline(s) they
reported using in practice i.e. aspirin-prescribers were
more likely to report using guidelines that accepted
aspirin as an appropriate thromboprophylactic measure
(38.6% vs. 12.4%, p < 0.001), and surgeons who preferred
only using anticoagulants were more likely to report
using a guideline that recommended against aspirin-use
post-arthroplasty (9.7% vs. 1.6%, p < 0.001]). It is unclear,
however, which factor influences the other i.e. are sur-
geons more likely to use a guideline that aligns with
their prescribing preference, or are they more likely to
prescribe a certain way based on the guideline they
decide or are required to use? Further research is
required to explore this.
A factor related to guideline use in Study 2 was guide-
line familiarity; surgeons were more likely to report
using a guideline if they reported being familiar with it,
suggesting that familiarity positively impacts uptake
(although the reverse may also be true). It should be
noted, however, that many surgeons who reported being
very familiar with a guideline still did not report using it
(72.9 to 93.9%, varying by guideline). Furthermore, our
findings suggest that in comparison to the combined
effects of research literature, experience and patient
complications (listed by 52.9% of surgeons as having
influenced their protocol), guidelines and local protocols
appear to exert a quantitatively smaller influence (only
listed by 16.2% of surgeons). Of all the guidelines report-
edly used by surgeons, the orthopaedic-specific ASA and
AAOS guidelines were the most popular. Compared to
other guidelines, these both include pharmacological
and non-pharmacological aspects of VTE prevention
(over and above mechanical prophylaxis recommenda-
tions) in their main body of recommendations.
As with all research, the findings of these studies must
be considered in light of their limitations. In particular,
we only collected surgeons’ descriptions of their throm-
boprophylaxis practices, which may not accurately rep-
resent their actual real-world practices. Secondly, while
our response rates were relatively high for this form of
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research, we cannot be certain that our invitation pools
included all eligible surgeons in Australia. The combined
annual arthroplasty load reported in our studies made
up approximately 44.4 and 61.8% of surgeries recorded
in the National Joint Replacement Registry in 2011 and
2016, respectively, and these proportions are similar to
the respective response rates (50.0 and 65.8%, respect-
ively) suggesting that the invitation pools were reason-
ably close to the actual eligible pool of hip and knee
surgeons in Australia at the time [1, 2]. In the absence
of being able to conduct a follow-up survey with
non-responders to compare their views and practices
with responders, we compared the responses from sur-
geons who responded to the first and third mail-outs in
Study 2. There was no meaningful difference in their
demographics, practices, or beliefs, suggesting that there
is a good chance that the views and practices of our
responders accurately reflect all surgeons conducting hip
and knee arthroplasty in Australia.
Conclusions
Our findings suggest that VTE prevention following hip
and knee arthroplasty is an evolving and multi-faceted
entity in Australia, with many different influencing fac-
tors and potentially some evidence-practice gaps that
need further exploring. It will be interesting to observe
whether the findings of the recently published EPACT II
[19] study have an impact on practice and lead to less
variation.
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